Paclitaxel and Estramustine in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

February 29, 1996

Primary Completion Date

September 30, 2006

Study Completion Date

September 30, 2006

Conditions
Lymphoma
Interventions
DRUG

estramustine phosphate sodium

DRUG

paclitaxel

Trial Locations (17)

15905

Conemaugh Memorial Hospital, Johnstown

16602

Bon Secours-Holy Family Health System, Altoona

19026

Delaware County Memorial Hospital, Drexel Hill

19047

Saint Mary Regional Center, Langhorne

19111

Fox Chase Cancer Center, Philadelphia

19464

Pottstown Memorial Regional Cancer Center, Pottstown

08822

Hunterdon Regional Cancer Center, Flemington

08701

Kimball Medical Center, Lakewood

08332

South Jersey Regional Cancer Center, Millville

08060

Fox Chase Cancer Center at Virtua Memorial Hospital Burlington County, Mount Holly

07701

Riverview Medical Center - Booker Cancer Center, Red Bank

08755

Community Medical Center, Toms River

08629

St. Francis Medical Center, Trenton

17105-8700

Pinnacle Health Hospitals, Harrisburg

19446-1200

North Penn Hospital, Lansdale

19301-1792

Paoli Memorial Hospital, Paoli

19612-6052

Reading Hospital and Medical Center, Reading

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Fox Chase Cancer Center

OTHER

NCT00021372 - Paclitaxel and Estramustine in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter